Phase II study of individualized sunitinib as first-line therapy for metastatic renal cell cancer (mRCC).
Georg A. Bjarnason(Sunnybrook Health Science Centre), Naveen S. Basappa, Eric Winquist(Western University), Ben Boyd(Ozmosis Research (Canada)), Sebastién J. Hotte(Juravinski Cancer Centre), Scott North, Denis Soulières(Centre Hospitalier de l’Université de Montréal), Jennifer J. Knox(National Cancer Center), Paweł Zalewski(Medical University of Warsaw), Piotr Czaykowski(CancerCare Manitoba), D. Scott Ernst, I. Tannock(Princess Margaret Cancer Centre), Christian Kollmannsberger(BC Cancer Agency), Bernhard J. Eigl(BC Cancer Agency), Christina M. Canil(University of Ottawa), Peter Venner(Cancer Institute (WIA)), Robyn Jane Macfarlane(Queen Elizabeth II Health Sciences Centre), Anil Kapoor(People’s University), Daniel Yick Chin Heng(University of Calgary), Aaron R. Hansen(Princess Margaret Cancer Centre)
Cited by 5
Related Papers
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|2.2k
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
|Journal of Clinical Oncology|2019|1.8k